Professor Maria Belvisi is head of the Respiratory Pharmacology group at the National Heart and Lung Institute, Imperial College, London.
Professor Belvisi is an internationally recognized expert in the respiratory field with both academic and industrial experience. Her research is focused on the cellular and molecular mechanisms of asthma, COPD and chronic cough, and developing therapies for these diseases. Her research is translational and takes data generated in vitro through to in vivo models and clinical studies with collaborators. Together with Peter Barnes at NHLI she was involved in generating key data sets during the developement of tiotropium bromide (Spiriva) a long acting muscarinig receptor antagonist used as a bronchodilator for the treatment of chronic obstructive pulmonary disease.
Professor Belvisi also worked for a period at Rhone-Poulenc Rorer/Aventis Pharma, leading a team in the company’s Respiratory Research Therapeutic area. During this time she was involved in the the development of Ciclesonide (Alvesco) an inhaled corticosteroid for asthma with an improved therapeutic ratio.
Professor Belvisi has an extensive publication record in peer review journals and serves on the editorial board of several publications. She has also received several prizes and awards, including the Women in Inflammation Science (2009), awarded by the World Inflammation Society, and the AstraZeneca Women in Pharmacology Prize (2011). She was elected fellow of the British Pharmacological Society in 2005.
In 2010 she formed, together with Dr Mark Birrell, IR Pharma a preclinical respiratory drug discovery organisation which is part of the Imperial Innovations portfolio of companies.
et al., 2021, The novel bronchodilator navafenterol: a phase 2a, multi-centre, randomised, double-blind, placebo-controlled crossover trial in COPD., Eur Respir J
et al., 2021, Targeting Alveolar Repair in Idiopathic Pulmonary Fibrosis, American Journal of Respiratory Cell and Molecular Biology, Vol:65, ISSN:1044-1549, Pages:347-365
et al., 2021, Advances in TRP channel drug discovery: from target validation to clinical studies, Nature Reviews Drug Discovery, ISSN:1474-1776
et al., 2021, Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3K gamma delta dual inhibitor targeting airway inflammatory disease, British Journal of Clinical Pharmacology, ISSN:0306-5251
et al., 2021, PI3K gamma d Inhibitor, AZD8154, Demonstrates Improved Efficacious Profile Over PI3Kd Selective Inhibitor, GSK2269557, in a Rat Model of Asthma, International Conference of the American-Thoracic-Society (ATS), AMER THORACIC SOC, ISSN:1073-449X